Y. Hei

Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

J. E. Brown, Richard J. Cook, Pierre Major et al. · JNCI Journal of the National Cancer Institute · 2005 · 564 citations · Full text

Medicine, Biostatistics, Oncology +16

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Hedy L. Kindler, Donald Richards, Lawrence Garbo et al. · Annals of Oncology · 2012 · 191 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

George R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon et al. · Annals of Oncology · 2011 · 92 citations

Medicine, Oncology, Pharmacology +12

Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis

Kaoru Kubota, Y. Ichinose, Giorgio V. Scagliotti et al. · Annals of Oncology · 2014 · 45 citations · Full text

Medicine, Oncology, Pharmacology +10

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications

Vera Hirsh, N. Simon Tchekmedyian, Lee S. Rosen et al. · Journal of Clinical Oncology · 2004 · 30 citations

Medicine, Oncology, Chemotherapy +16